HORIZON-HLTH-2021-CORONA-01
HORIZON-HLTH-2021-CORONA-01
- Programme
- HORIZON
- Funded projects (dataset)
- 10
- EU contribution (sum)
- €102,670,941
- Portal deadline
- —
Leading topic in historical projects: HORIZON-HLTH-2021-CORONA-01-01
Start here
Suggested partners for this call
Who coordinated consortia under this call, plus a complementary slice (topic leaders, research partners, or frequent non-coordinators). For industry lists, CSV export, and consortium size — open Proposal partner finder.
Top coordinators
Organisations that coordinated the most funded projects under this call.
- CHUV1 coordinated
- EuResist1 coordinated
- EXEVIR BIO1 coordinated
- FABENTECH1 coordinated
- HIPRA SCIENTIFIC1 coordinated
- GUF1 coordinated
- METRIOPHARM AG1 coordinated
- Ecraid1 coordinated
- UNIPD1 coordinated
- UNIVERSITY COLLEGE LONDON1 coordinated
Organisations strong on this topic
Broader signal: frequent participants across funded projects tagged with the same topic codes as this call (not limited to coordinators).
- ICS3 topic projects
- NORWEGIAN INSTITUTE OF PUBLIC HEALTH NIPH2 topic projects
- FONDAZIONE PENTA ETS2 topic projects
- FIB-H12O2 topic projects
- HOSPITAL CLINIC DE BARCELONA2 topic projects
- IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE2 topic projects
- INSERM2 topic projects
- SU UNIVERSITY OF STELLENBOSCH2 topic projects
- UMIL2 topic projects
- UMC UTRECHT2 topic projects
- UNIGE2 topic projects
- UANTWERPEN2 topic projects
Frequent collaborators
Pairs that often appear together in the same funded project under this call.
- ICS · HOSPITAL CLINIC DE BARCELONA2 shared
ES ↔ ES
- 2 shared
- INSERM · SU UNIVERSITY OF STELLENBOSCH2 shared
FR ↔ ZA
- 2 shared
- 2 shared
- UANTWERPEN · UMC UTRECHT2 shared
BE ↔ NL
- UCT · SU UNIVERSITY OF STELLENBOSCH2 shared
ZA ↔ ZA
- KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT · CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY1 shared
DE ↔ RO
- KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT · UNIVERSITAIR MEDISCH CENTRUM GRONINGEN1 shared
DE ↔ NL
- 1 shared
- KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT · ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1 shared
DE ↔ FR
- 1 shared
- 1 shared
- 1 shared
- 1 shared
- 1 shared
- 1 shared
- EuResist · IBM ISRAEL1 shared
IT ↔ IL
Proposal partner finder
One page with suggested coordinators, strong and industry partners, topic leaders, typical consortium size, similar projects — plus CSV or print / PDF export for your shortlist.
Typical consortium pattern
Derived from historical funded projects linked to this CORDIS call in Grantibase.
- Avg. orgs / project
- 15.4
- Median orgs / project
- 17
- Min / max orgs
- 4 – 34
Country presence
Participant rows (an org can appear in multiple countries if data varies).
- Spain27
- Italy19
- Germany16
- Switzerland12
- Belgium9
- Netherlands8
- United Kingdom7
- France7
- South Africa6
- Portugal4
- Norway3
- Austria3
- United States3
- Thailand2
- Israel2
- Nigeria2
- Brazil2
- Lithuania2
Organization types
- university46 orgs · 55 rows
- research_institute35 orgs · 39 rows
- company21 orgs · 21 rows
- other16 orgs · 17 rows
- public_body10 orgs · 12 rows
- sme10 orgs · 10 rows
Topics in funded projects
- HORIZON-HLTH-2021-CORONA-01-01HORIZON-HLTH-2021-CORONA-01-01· 5 projects
- HORIZON-HLTH-2021-CORONA-01-02HORIZON-HLTH-2021-CORONA-01-02· 5 projects
Related funded projects
Largest EU contributions in this call — useful to see who already won funding on similar lines.
Open full project list in advanced search
| Project | Programme | EU contribution |
|---|---|---|
| VERDI SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts | HORIZON | €15,395,599 |
| END-VOC ENDING COVID 19 VARIANTS OF CONCERN THROUGH COHORT STUDIES: END-VOC | HORIZON | €10,496,137 |
| CoVICIS EU-Africa Concerted Action on SAR-CoV-2 Virus Variant and Immunological Surveillance | HORIZON | €10,048,971 |
| ECRAID-Prime European Clinical Research Alliance on Infectious Diseases - PRIMary care adaptive platform trial for pandemics and Epidemics | HORIZON | €9,998,518 |
| EuCARE European Cohorts of Patients and Schools to Advance Response to Epidemics | HORIZON | €9,995,920 |
| COVend Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19 | HORIZON | €9,994,978 |
| XVR011 Phase 2 ExeVir's XVR011, a best in class nanobody-based biology that broadly neutralizes SARS-COV-1 and SARS-COV-2 | HORIZON | €9,902,750 |
| RBDCOV RBD Dimer recombinant protein vaccine against SARSCoV2 | HORIZON | €9,779,211 |
| EPIC-CROWN-2 Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2–VOC | HORIZON | €9,070,134 |
| iMPact Novel, orally available immune modulator MP1032 with anti-SARS-CoV-2 and anti-cytokine activity | HORIZON | €7,988,724 |